Literature DB >> 29134363

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.

Ahmet Emre Eskazan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29134363     DOI： 10.1007/s10147-017-1214-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  5 in total

1.  Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Authors:  Ahmet Emre Eskazan; Deniz Ozmen
Journal:  Expert Rev Hematol       Date:  2017-06-13       Impact factor: 2.929

Review 2.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Authors:  Simona Soverini; Andreas Hochhaus; Franck E Nicolini; Franz Gruber; Thoralf Lange; Giuseppe Saglio; Fabrizio Pane; Martin C Müller; Thomas Ernst; Gianantonio Rosti; Kimmo Porkka; Michele Baccarani; Nicholas C P Cross; Giovanni Martinelli
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

3.  Moving treatment-free remission into mainstream clinical practice in CML.

Authors:  Timothy P Hughes; David M Ross
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

4.  Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.

Authors:  Ahmet Emre Eskazan; Deniz Eyice; Enes Ali Kurt; Tugrul Elverdi; Fevzi Firat Yalniz; Ayse Salihoglu; Muhlis Cem Ar; Seniz Ongoren Aydin; Zafer Baslar; Burhan Ferhanoglu; Yildiz Aydin; Nukhet Tuzuner; Ugur Ozbek; Teoman Soysal
Journal:  Leuk Res       Date:  2014-04-18       Impact factor: 3.156

5.  Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.

Authors:  Masayuki Shiseki; Chikashi Yoshida; Naoki Takezako; Akira Ohwada; Takashi Kumagai; Kaichi Nishiwaki; Akira Horikoshi; Tetsuya Fukuda; Hina Takano; Yasuji Kouzai; Junji Tanaka; Satoshi Morita; Junichi Sakamoto; Hisashi Sakamaki; Koiti Inokuchi
Journal:  Int J Clin Oncol       Date:  2017-05-26       Impact factor: 3.402
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.